2. Search Result
Search Result
Results for "

macular

" in MedChemExpress (MCE) Product Catalog:

67

Inhibitors & Agonists

6

Peptides

9

Inhibitory Antibodies

7

Natural
Products

1

Isotope-Labeled Compounds

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116098
    Anecortave desacetate

    AL-4940

    		 Biochemical Assay Reagents Cancer
    Anecortave desacetate (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors .
    Anecortave desacetate
  • HY-P99116
    Faricimab

    RG7716

    		 VEGFR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
    Faricimab
  • HY-P99629
    Galegenimab

    FHTR 2163; RG 6147; RO 7171009

    		 Ser/Thr Protease Neurological Disease
    Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .
    Galegenimab
  • HY-P3204
    POT-4
    1 Publications Verification

    AL-78898A

    		 Complement System Metabolic Disease
    POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
    POT-4
  • HY-114653
    SRPIN803

    		Casein Kinase SRPK Cancer
    SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC50s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .
    SRPIN803
  • HY-P99576
    Tarcocimab

    OG1953

    		 VEGFR Others
    Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
    Tarcocimab
  • HY-P1930A
    Risuteganib hydrochloride

    		Integrin Inflammation/Immunology
    Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
    Risuteganib hydrochloride
  • HY-P3204A
    POT-4 TFA

    AL-78898A TFA

    		 Complement System Metabolic Disease
    POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .
    POT-4 TFA
  • HY-136788A
    ALK4290 dihydrochloride

    AKST4290 dihydrochloride

    		 CCR Inflammation/Immunology
    ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .
    ALK4290 dihydrochloride
  • HY-143476
    Plasma kallikrein-IN-2

    		Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-2
  • HY-P1930
    Risuteganib

    		Integrin Inflammation/Immunology
    Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
    Risuteganib
  • HY-136788
    ALK4290

    AKST4290

    		 CCR Neurological Disease Inflammation/Immunology
    ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .
    ALK4290
  • HY-N11286
    Tridocosahexaenoylglycerol

    TG-DHA; Meganol D

    		 Others Neurological Disease Metabolic Disease Inflammation/Immunology
    Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .
    Tridocosahexaenoylglycerol
  • HY-163690
    HTRA1-IN-1

    		Ser/Thr Protease Inflammation/Immunology
    HTRA1-IN-1 (Compound 17) is a selective inhibitor for serine protease high temperature requirement A serine peptidase 1 (HTRA1), with IC50 of 13 nM. HTRA1-IN-1 is potential for ameliorating HTRA1-related diseases, such as age-related macular degeneration (AMD), osteoarthritis, and rheumatoid arthritis .
    HTRA1-IN-1
  • HY-106429
    OT-551 free base

    		Others Others
    OT-551 (free base) is a lipophilic, disubstituted hydroxylamine with antioxidant properties. OT-551 can be used as an eye drop and can be converted by intraocular esterases to its active metabolite, Tempol-H (TP-H). OT-551 can be utilized in geographic atrophy and macular degeneration research .
    OT-551 free base
  • HY-N11286R
    Tridocosahexaenoylglycerol (Standard)

    		Others Neurological Disease Metabolic Disease Inflammation/Immunology
    Tridocosahexaenoylglycerol (Standard) is the analytical standard of Tridocosahexaenoylglycerol. This product is intended for research and analytical applications. Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .
    Tridocosahexaenoylglycerol (Standard)
  • HY-P99298
    Lampalizumab

    RG 7417; TNX 234; Anti-CFD Recombinant Antibody

    		 Complement System Inflammation/Immunology
    Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
    Lampalizumab
  • HY-P9951A
    Ranibizumab (anti-VEGF)

    RG-6321 (anti-VEGF)

    		 VEGFR Cardiovascular Disease
    Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
    Ranibizumab (anti-VEGF)
  • HY-110195
    Smurf1-IN-A01
    1 Publications Verification

    A01

    		 HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR Others Cancer
    Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .
    Smurf1-IN-A01
  • HY-19720
    Emixustat

    ACU-4429

    		 Others Metabolic Disease
    Emixustat is an orally active RPE65 inhibitor with an IC50 value of 4.4 nM. Emixustat is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD) .
    Emixustat
  • HY-P99905
    Efdamrofusp alfa

    		VEGFR Cardiovascular Disease Neurological Disease
    Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
    Efdamrofusp alfa
  • HY-19720A
    Emixustat hydrochloride

    ACU-4429 hydrochloride

    		 Others Metabolic Disease
    Emixustat (ACU-4429) hydrochloride is an orally active RPE65 inhibitor with an IC50 value of 4.4 nM. Emixustat hydrochloride is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD) .
    Emixustat hydrochloride
  • HY-148457
    Avacincaptad pegol

    		Complement System Infection Inflammation/Immunology
    Avacincaptad pegol, which is a pegylated aptamer, has garnered significant attention as a C5 complement inhibitor that may reduce inflammation-related retinal pigment epithelium (RPE) damage. Avacincaptad pegol caqn be used for the research of stargardt macular dystrophy (STGD1) and geographic atrophy (GA) .
    Avacincaptad pegol
  • HY-147080
    Avacincaptad pegol sodium

    ARC1905

    		 Complement System Others
    Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system. Avacincaptad pegol sodium treats Geographic atrophy (GA) mice .
    Avacincaptad pegol sodium
  • HY-P3252A
    Pegcetacoplan acetate

    		Complement System Inflammation/Immunology
    Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia .
    Pegcetacoplan acetate
  • HY-150069
    UBX1325

    		Bcl-2 Family Apoptosis Metabolic Disease
    UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
    UBX1325
  • HY-B0580
    Ketorolac
    1 Publications Verification

    RS37619

    		 COX Apoptosis Inflammation/Immunology Cancer
    Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research .
    Ketorolac
  • HY-B0580D
    Ketorolac hydrochloride

    RS37619 hydrochloride

    		 COX Apoptosis Inflammation/Immunology Cancer
    Ketorolac (RS37619) hydrochloride is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac hydrochloride tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac hydrochloride tromethamine is also a DDX3 inhibitor that can be used for cancer research .
    Ketorolac hydrochloride
  • HY-B0580C
    Ketorolac hemicalcium

    RS37619 hemicalcium

    		 COX Apoptosis Inflammation/Immunology Cancer
    Ketorolac (RS37619) hemicalcium is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorola chemicalcium is also a DDX3 inhibitor that can be used for cancer research .
    Ketorolac hemicalcium
  • HY-16467
    Squalamine lactate

    MSI-1256F

    		 Bacterial Infection Cardiovascular Disease Cancer
    Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.
    Squalamine lactate
  • HY-B0580R
    Ketorolac (Standard)

    		COX Apoptosis Inflammation/Immunology Cancer
    Ketorolac (Standard) is the analytical standard of Ketorolac. This product is intended for research and analytical applications. Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research .
    Ketorolac (Standard)
  • HY-P99402
    Rinucumab

    REGN 2176

    		 PDGFR Metabolic Disease
    Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
    Rinucumab
  • HY-15492A
    AG-13958 (mono(hydrochloride))

    AG-013958 monohydrochloride

    		 VEGFR Cardiovascular Disease
    AG-13958 monohydrochloride, a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958 (mono(hydrochloride))
  • HY-15492
    AG-13958
    1 Publications Verification

    AG-013958

    		 VEGFR Cardiovascular Disease
    AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958
  • HY-109561
    Pegaptanib sodium

    EYE001; NX1838

    		 VEGFR Metabolic Disease Inflammation/Immunology
    Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
    Pegaptanib sodium
  • HY-150052
    Plasma kallikrein-IN-3

    		Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-3
  • HY-132126
    SPHINX

    		SRPK Others
    SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD .
    SPHINX
  • HY-158821
    ISTH0036

    		TGF-beta/Smad Others
    ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), can be use in the study of primary open angle glaucoma (POAG), and wet age-related macular degeneration.
    ISTH0036
  • HY-158821A
    ISTH0036 sodium

    		TGF-beta/Smad Others
    ISTH0036 sodium, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), can be use in the study of primary open angle glaucoma (POAG) , and wet age-related macular degeneration.
    ISTH0036 sodium
  • HY-163403
    VEGFR-2-IN-43

    		VEGFR Cardiovascular Disease Cancer
    VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC50 of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .
    VEGFR-2-IN-43
  • HY-153484A
    Bevasiranib sodium

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib sodium
  • HY-153484
    Bevasiranib

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib
  • HY-116312
    8-CPT-2'-O-Me-cAMP

    		Ras Cardiovascular Disease
    8-CPT-2'-O-Me-cAMP is a Rap1 activator. 8-CPT-2'-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .
    8-CPT-2'-O-Me-cAMP
  • HY-153183
    Lp-PLA2-IN-12

    		Phospholipase Cardiovascular Disease Neurological Disease
    Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .
    Lp-PLA2-IN-12
  • HY-B0146
    Verteporfin
    Maximum Cited Publications
    167 Publications Verification

    CL 318952

    		 YAP Apoptosis Autophagy Cancer
    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
    Verteporfin
  • HY-108801
    Aflibercept

    VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

    		 VEGFR Cardiovascular Disease Metabolic Disease Cancer
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
    Aflibercept
  • HY-108801A
    Aflibercept (VEGF Trap)

    		VEGFR Cardiovascular Disease Metabolic Disease Cancer
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
    Aflibercept (VEGF Trap)
  • HY-113127
    L-Tryptophanamide

    		Others Others
    L-Tryptophanamide is a compound discovered in wet age-related macular degeneration research, which has activities related to affecting retinal cell proliferation, apoptosis, necrosis and angiogenesis. In in vitro experiments, L-Tryptophanamide affects the proliferation, apoptosis and necrosis of human retinal pigment epithelial cells, and promotes tube formation and migration of human retinal endothelial cells.
    L-Tryptophanamide
  • HY-132830
    Sebetralstat

    KVD900

    		 Kallikrein Metabolic Disease
    Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases .
    Sebetralstat
  • HY-128973
    Pyropheophorbide-a

    		Reactive Oxygen Species Cancer
    Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .
    Pyropheophorbide-a

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: